Shape Therapeutics to Highlight RNA Editing Technology Platform Advancements in Parkinson’s Disease and the Identification of Novel CNS-targeting AAV Variants at the J.P. Morgan 39th Annual Healthcare Conference

“RNA is the software of life. We now have next-generation tools to 'debug' the source code of genetic diseases like Parkinson's by targeting RNA directly in the brain. It will be quite exciting to move our RNA editing and tissue-specific AAV delivery technology to the next phase of their development," said Francois Vigneault, PhD., President and CEO.

About Shape Therapeutics Inc

Shape Therapeutics is a biotechnology company developing next-generation gene therapy technologies to treat the world’s most challenging diseases. Shape^TX gene therapy platform comprises RNAskip™, RNAfix™, and RNAswitch™ payload technology, next-generation tissue-specific AAVid™ delivery technology, and SquareBio, a solution to scalable gene therapy manufacturing based on industrialization of human stable cell lines. The power of the Shape^TX resides in its core AI discovery platform, where data drives decisions in building technology today to enable gene therapies of tomorrow. Shape^TX is committed to data-driven scientific advancement, passionate people, and a mission of providing life-long cures to patients. Shape Life!

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005418/en/